{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:37:48Z","timestamp":1792204668414,"version":"4.4.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"14-15","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2024,10,12]]},"DOI":"10.1080\/14622416.2024.2441104","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:49:49Z","timestamp":1734598189000},"page":"623-635","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic review"],"prefix":"10.1080","volume":"25","author":[{"given":"Lisanne A.H.","family":"Bevers","sequence":"first","affiliation":[{"name":"Radboud University Medical Center","place":["Nijmegen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2869","authenticated-orcid":false,"given":"Rebecca L.","family":"Jensen","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center","place":["Nijmegen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Carr","sequence":"additional","affiliation":[{"name":"University of Liverpool","place":["Liverpool, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center","place":["Nijmegen, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Organisation WH. Consolidated guidelines on HIV prevention testing treatment service delivery and monitoring. 2021."},{"issue":"11","key":"e_1_3_5_3_1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell ML","year":"2013","unstructured":"Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981\u2013994.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"e_1_3_5_4_1","article-title":"Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial","volume":"7","author":"Bollen PDJ","year":"2020","unstructured":"Bollen PDJ, Moore CL, Mujuru HA, et al. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. The Lancet HIV. 2020;7(8):e533\u2010e44.","journal-title":"The Lancet HIV"},{"issue":"5","key":"e_1_3_5_5_1","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(21)00292-7","article-title":"Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial","volume":"9","author":"Waalewijn H","year":"2022","unstructured":"Waalewijn H, Chan MK, Bollen PDJ, et al. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. The Lancet HIV. 2022;9(5):e341\u2010e52.","journal-title":"The Lancet HIV"},{"issue":"9","key":"e_1_3_5_6_1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciad346","article-title":"Pharmacokinetic data of dolutegravir in second-line treatment of children living with HIV: results from the CHAPAS4-trial","volume":"77","author":"Bevers L","year":"2023","unstructured":"Bevers L, Waalewijn H, Szubert A, et al. Pharmacokinetic data of dolutegravir in second-line treatment of children living with HIV: results from the CHAPAS4-trial. Clin Infect Dis. 2023;77(9): 1312\u20131317.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"e_1_3_5_7_1","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(22)00044-3","article-title":"Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1\u20132 trial","volume":"9","author":"Ruel TD","year":"2022","unstructured":"Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1\u20132 trial. Lancet HIV. 2022;9(5):e332\u2013e40.","journal-title":"Lancet HIV"},{"issue":"9","key":"e_1_3_5_8_1","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1093\/jac\/dkz217","article-title":"Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting","volume":"74","author":"Barcelo C","year":"2019","unstructured":"Barcelo C, Aouri M, Courlet P, et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother. 2019;74(9): 2690\u20132697.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"e_1_3_5_9_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciy426","article-title":"Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition","volume":"68","author":"Elliot ER","year":"2019","unstructured":"Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019;68(1):87\u201395.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"e_1_3_5_10_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000001781","article-title":"Adverse drug reactions to integrase strand transfer inhibitors","volume":"32","author":"Lepik KJ","year":"2018","unstructured":"Lepik KJ, Yip B, Ulloa AC, et al. Adverse drug reactions to integrase strand transfer inhibitors. AIDS. 2018;32(7):903\u2013912.","journal-title":"AIDS"},{"issue":"6","key":"e_1_3_5_11_1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"Penafiel J","year":"2017","unstructured":"Penafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752\u20131759.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"e_1_3_5_12_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann C","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56\u201363.","journal-title":"HIV Med"},{"issue":"2","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese MJ","year":"2013","unstructured":"Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353\u2013361.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"e_1_3_5_14_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1124\/dmd.110.037192","article-title":"The development of udp-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver","volume":"39","author":"Miyagi SJ","year":"2011","unstructured":"Miyagi SJ, Collier AC. The development of udp-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos. 2011;39(5):912\u2013919.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"e_1_3_5_15_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","article-title":"Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV","volume":"32","author":"Mulligan N","year":"2018","unstructured":"Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729\u2013737.","journal-title":"AIDS"},{"issue":"11","key":"e_1_3_5_16_1","doi-asserted-by":"crossref","first-page":"e1002160","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente G","year":"2016","unstructured":"Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLOS Med. 2016;13(11):e1002160.","journal-title":"PLOS Med"},{"key":"e_1_3_5_17_1","doi-asserted-by":"crossref","first-page":"655320","DOI":"10.3389\/fphar.2021.655320","article-title":"Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes","volume":"12","author":"Khatri R","year":"2021","unstructured":"Khatri R, Fallon JK, Sykes C, et al. Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes. Front Pharmacol. 2021;12:655320.","journal-title":"Front Pharmacol"},{"issue":"7","key":"e_1_3_5_18_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","article-title":"Prescribing issues in elderly individuals living with HIV","volume":"12","author":"Marzolini C","year":"2019","unstructured":"Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol. 2019;12(7):643\u2013659.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"e_1_3_5_19_1","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.","journal-title":"PLOS Med"},{"issue":"1","key":"e_1_3_5_20_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"issue":"1","key":"e_1_3_5_21_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/pgs.13.190","article-title":"Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics","volume":"15","author":"Chen S","year":"2014","unstructured":"Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15(1):9\u201316.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"e_1_3_5_22_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","article-title":"Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1","volume":"17","author":"Yagura H","year":"2017","unstructured":"Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"e_1_3_5_23_1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/jac\/dkz558","article-title":"Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics","volume":"75","author":"Elliot ER","year":"2020","unstructured":"Elliot ER, Neary M, Else L, et al. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. J Antimicrob Chemother. 2020;75(5):1259\u20131266.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"e_1_3_5_24_1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/infdis\/jiac174","article-title":"Pharmacogenetics of dolutegravir plasma exposure among southern Africans with human immunodeficiency virus","volume":"226","author":"Cindi Z","year":"2022","unstructured":"Cindi Z, Kawuma AN, Maartens G, et al. Pharmacogenetics of dolutegravir plasma exposure among southern Africans with human immunodeficiency virus. J Infect Dis. 2022;226(9):1616\u20131625.","journal-title":"J Infect Dis"},{"issue":"3","key":"e_1_3_5_25_1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0000000000003358","article-title":"Impact of genetic variants in ABCG2, NR1I2, and UGT1A1 on the pharmacokinetics of dolutegravir in children","volume":"95","author":"Spector SA","year":"2024","unstructured":"Spector SA, Brummel SS, Chang A, et al. Impact of genetic variants in ABCG2, NR1I2, and UGT1A1 on the pharmacokinetics of dolutegravir in children. J Acquired Immune Deficiency Syndr. 2024;95(3):297\u2013303.","journal-title":"J Acquired Immune Deficiency Syndr"},{"issue":"11","key":"e_1_3_5_26_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FPC.0000000000000308","article-title":"High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants","volume":"27","author":"Tsuchiya K","year":"2017","unstructured":"Tsuchiya K, Hayashida T, Hamada A, et al. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genomics. 2017;27(11):416\u2013419.","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"e_1_3_5_27_1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/metabo12121202","article-title":"Dolutegravir discontinuation for neuropsychiatric symptoms in people living with HIV and Their outcomes after treatment change: a pharmacogenetic study","volume":"12","author":"Cusato J","year":"2022","unstructured":"Cusato J, Borghetti A, Teti E, et al. Dolutegravir discontinuation for neuropsychiatric symptoms in people living with HIV and Their outcomes after treatment change: a pharmacogenetic study. Metabolites. 2022;12(12):1202.","journal-title":"Metabolites"},{"issue":"5","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181f0634c","article-title":"The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy","volume":"32","author":"Cabrera Figueroa S","year":"2010","unstructured":"Cabrera Figueroa S, Fern\u00e1ndez de Gatta M, Hern\u00e1ndez Garc\u00eda L, et al. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. Ther Drug Monit. 2010;32(5):579\u2013585.","journal-title":"Ther Drug Monit"},{"key":"e_1_3_5_29_1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2012.00236","article-title":"ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV\/AIDS patients","volume":"3","author":"Swart M","year":"2012","unstructured":"Swart M, Ren Y, Smith P, et al. ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV\/AIDS patients. Front Genet. 2012;3:236.","journal-title":"Front Genet"},{"issue":"5","key":"e_1_3_5_30_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study","volume":"202","author":"Ribaudo HJ","year":"2010","unstructured":"Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. J Infect Dis. 2010;202(5):717\u2013722.","journal-title":"J Infect Dis"},{"issue":"1","key":"e_1_3_5_31_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/QAI.0000000000000893","article-title":"Brief report: high peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants","volume":"72","author":"Tsuchiya K","year":"2016","unstructured":"Tsuchiya K, Hayashida T, Hamada A, et al. Brief report: high peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. J Acquired Immune Deficiency Syndr. 2016;72(1):11\u201314.","journal-title":"J Acquired Immune Deficiency Syndr"},{"issue":"2","key":"e_1_3_5_32_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-hiv drugs","volume":"59","author":"Weiss J","year":"2007","unstructured":"Weiss J, Rose J, Storch CH, et al. Modulation of human BCRP (ABCG2) activity by anti-hiv drugs. J Antimicrob Chemother. 2007;59(2):238\u2013245.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1128\/AAC.00781-10","article-title":"Population pharmacokinetic modeling of the association between 63396C->t pregnane X receptor polymorphism and unboosted atazanavir clearance","volume":"54","author":"Schipani A","year":"2010","unstructured":"Schipani A, Siccardi M, D\u2019Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C->t pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010;54(12):5242\u20135250.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"e_1_3_5_34_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dky508","article-title":"SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV","volume":"74","author":"Borghetti A","year":"2019","unstructured":"Borghetti A, Calcagno A, Lombardi F, et al. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. J Antimicrob Chemother. 2019;74(4):1035\u20131043.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_35_1","unstructured":"U.S. Food and Drug administration (FDA). Clinical pharmacology and biopharmaceutics review. Dolutegravir (Tivicay). 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204790Orig1s000ClinPharmR.pdf"},{"issue":"4","key":"e_1_3_5_36_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciz256","article-title":"Dolutegravir-based antiretroviral therapy for patients Co-infected with tuberculosis and hiv: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley KE","year":"2019","unstructured":"Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients Co-infected with tuberculosis and hiv: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2019;70(4):549\u2013556.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_5_37_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/wellcomeopenres.16473.1","article-title":"Standard versus double dose dolutegravir in patients with hiv-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial","volume":"6","author":"Griesel R","year":"2021","unstructured":"Griesel R, Hill A, Meintjes G, et al. Standard versus double dose dolutegravir in patients with hiv-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. Wellcome Open Res. 2021;6:1.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"e_1_3_5_38_1","first-page":"18","article-title":"Pk and safety of high-dose rifampicin in TB\/HIV coinfected patients on EFV or DTG","volume":"29","author":"Sekaggya-Wiltshire C","year":"2021","unstructured":"Sekaggya-Wiltshire C, Nabisere R, Musaazi J, et al. Pk and safety of high-dose rifampicin in TB\/HIV coinfected patients on EFV or DTG. Top Antivir Med. 2021;29(1):18.","journal-title":"Top Antivir Med"},{"issue":"4","key":"e_1_3_5_39_1","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax PE","year":"2017","unstructured":"Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154\u2013e60.","journal-title":"Lancet HIV"},{"key":"e_1_3_5_40_1","article-title":"Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort","author":"Ciccullo A","year":"2024","unstructured":"Ciccullo A, Baldin G, Cervo A, et al. Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort. J Antimicrob Chemother. 2024.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_41_1","article-title":"Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy","author":"Andreatta K","year":"2024","unstructured":"Andreatta K, Sax PE, Wohl D, et al. Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. J Antimicrob Chemother. 2024.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_42_1","first-page":"9s","article-title":"Switch to bictegravir\/f\/taf from DTG and ABC\/3TC","volume":"26","author":"Molina JM","year":"2018","unstructured":"Molina JM, Ward D, Brar I, et al. Switch to bictegravir\/f\/taf from DTG and ABC\/3TC. Top Antivir Med. 2018;26:9s.","journal-title":"Top Antivir Med"},{"issue":"7","key":"e_1_3_5_43_1","doi-asserted-by":"crossref","first-page":"e030212","DOI":"10.1136\/bmjopen-2019-030212","article-title":"Protocol for the development of the STrengthening the reporting of pharmacogenetic studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies","volume":"9","author":"Richardson M","year":"2019","unstructured":"Richardson M, Kirkham JJ, Dwan KM, et al. Protocol for the development of the STrengthening the reporting of pharmacogenetic studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. BMJ Open. 2019;9(7):e030212.","journal-title":"BMJ Open"},{"issue":"9","key":"e_1_3_5_44_1","doi-asserted-by":"crossref","first-page":"e1003344","DOI":"10.1371\/journal.pmed.1003344","article-title":"Strengthening the reporting of pharmacogenetic studies: development of the STROPS guideline","volume":"17","author":"Chaplin M","year":"2020","unstructured":"Chaplin M, Kirkham JJ, Dwan K, et al. Strengthening the reporting of pharmacogenetic studies: development of the STROPS guideline. PLOS Med. 2020;17(9):e1003344.","journal-title":"PLOS Med"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14622416.2024.2441104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:40:38Z","timestamp":1739184038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14622416.2024.2441104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":43,"journal-issue":{"issue":"14-15","published-print":{"date-parts":[[2024,10,12]]}},"alternative-id":["10.1080\/14622416.2024.2441104"],"URL":"https:\/\/doi.org\/10.1080\/14622416.2024.2441104","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}